Ono’s Strengths & Characteristics
R&D
Social Responsibility
Corporate Slogan
New drugs are created by overcoming many challenges and failures. Our corporate slogan, “BREAK THROUGH - Embrace the Challenge with ONO -,” expresses our belief that tackling new challenges will lead to a brighter future, and we will keep striving tirelessly toward making that a reality.
-
more
Management / Finance
Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation
-
more
R & D
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate
-
more
R & D
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of OPDIVO for the Treatment of Unresectable Anaplastic Thyroid Cancer
-
more
R & D
Bristol Myers Squibb Announces OPDIVO® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
-
more
R & D
Ono Pharma Announces Oral Presentation of New Data from Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
-
more
Corporate
Voting Results (Extraordinary Report) of the 78th Ordinary General Shareholders’ Meeting
-
more
Corporate
Notice to Resolutions Passed at the 78th Ordinary General shareholders’ Meeting
-
more
Corporate
Posting the script from the R&D Day event held on June 8
-
more
Corporate
Notice to Convene the 78th Ordinary General Shareholders’ Meeting
-
more
Corporate
Notice about Posting of the Financial Result Meeting for FY2025 - Script